MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome
LA JOLLA, Calif., April 12, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded…